Safety and efficacy of loteprednol for ocular inflammation: a meta-analysis
- VernacularTitle:氯替泼诺控制眼部炎症的安全性和有效性的荟萃分析
- Author:
Jinwei CHENG
;
Ruili WEI
;
You LI
- Publication Type:Journal Article
- Keywords:
intraocular pressure;
endoph-thalmia;
meta-analysis;
placebos;
prednisolone;
loteprednol
- From:
Chinese Journal of New Drugs and Clinical Remedies
2003;22(5):259-263
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To evaluate the safety and efficacy of loteprednol for controlling of ocular inflammation. METHODS: Data from 8 relevant monographs were retrieved by means of computerized and manual search. The combined analysis of the data was assessed in terms of clinical and statistical criteria, and the data were extracted and synthesized by using the statistical techniques of meta-analysis. Treatment effects and safety of loteprednol were through counting as risk difference between treatment and control groups. The estimates of pooled risk differences were computed according to a random-effects model. RESULTS: A total of 1 660 patients were included in this meta-analysis. Pooled risk differences of intraocular pressure elevation were 1 % (95 % CI, -1 %, 3 %) compared with placebo, -5 % (95 % CI, -9 %, 0 %) compared with prednisolone, respectively. Compared with placebo, pooled risk differences of inflammation improvement were: 31 % (95 % CI, 22 %, 40 %) of postoperative inflammation, 28 % (95 % CI, 19 %, 37 %) of seasonal allergic conjunctivitis, and 26 % (95 % CI, 18 %, 35 %) of giant papillary conjunctivitis, respectively. Compared with prednisolone, pooled risk differences of inflammation improvement of acute anterior uveitis was -15 % (95 % CI, -25 %, -4 %). CONCLUSION: Loteprednol is a safe and effective corticosteroid in controlling ocular inflammation such as postoperative inflammation, seasonal allergic conjunctivitis, giant papillary conjunctivitis, and acute anterior uveitis.
